From Pathogen to Infectious Disease Diagnosis: Taking on Potential Standard-of-Care Diagnostic Opportunities
In the second episode with Michael Laposata, MD, PhD, he discusses how lab professionals can communicate with infectious disease clinicians, how AI can be used in diagnostics, and potential point-of-care diagnostic opportunities for the lab.
In the first episode, Michael Laposata, MD, PhD, who is the professor and chair of the Department of Pathology at the University of Texas Medical Branch-Galveston discussed the evolution of how he developed the concept of the Diagnostic Management Team (DMT), which brings lab professionals out of the lab and looks to aid clinicians with interpretation of testing results.1 Additionally, his school, the University of Texas Medical Branch-Galveston, was one of the first universities in the United States that developed a Doctorate of Clinical Laboratory Studies (DCLS) program around the DMT concept.
Today’s episode is the second of a 2-part interview on the DMT novel concept and this evolving field.
In his conversation with our podcast host, Rodney E. Rohde, PhD, SV/SM/MB(ASCP)CM, FACSc, Laposata discusses the idea of laboratory professionals getting out of the lab and breaking down the silos between the lab and clinicians, the further development of the DMT concept and universities that are offering the DCLS program, and how the lab professionals can be a point-of-care for uncertain diagnoses, which may help decrease unnecessary treatment, and lead to optimal outcomes.
“The goal for us, which I think has kept us totally focused, is the patient. What we really want to do is to see that the diagnostic errors in America go as low as possible… Everybody knows it's a problem, and nobody's got an answer—until now.
— Michael Laposata, MD, PhD
Sit back and enjoy the episode. And if you have any ideas for future podcasts or feedback on this one, please email John Parkinson at jparkinson@mjhlifesciences.com.
To watch the first episode, interested viewers can go here.
